reference/18963101

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18963101

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
issn	2162-402X
issueIdentifier	1
pageRange	1731072-
publicationName	OncoImmunology
startingPage	1731072
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_cc62abbf723f9ea58577d84dc2b085d4 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_3fa620b8ebbbbc703e65465233371133 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b1bf1e4a00e9f9b1ea299f40a3e546a2 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_487baf6554eb36bb22c6138d90a7c50f
bibliographicCitation	Nie W, Qian J, Xu MD, Gu K, Qian FF, Hu MJ, Lu J, Gan L, Zhang XY, Cao SH, Li JW, Wang Y, Zhang B, Wang SY, Hu F, Li CH, Zhong H, Han BH. A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab. Oncoimmunology. 2020;9(1):1731072. PMID: 32158623; PMCID: PMC7051187.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4f414fa6845f7d062ddf26dc0d89d635 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_33c2957b52eb78c3955e613324c274c4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7343-9706 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b897334bc30282075eda136fa8e49004 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1827c91f5853316db276f934f6f957b8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7ccc7f41a6275e8391223c9e7f83267 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e9acf0dfebac388eb848f2943d3990bb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c621fc24b473dfbeea41648a6f44c8ce http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_55fe0f03db103274d24448967eea1fc6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5824df5d9c67fb14b44f8a91b40af352 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c6c7fb4bfd5a94d199da4ccf53326e38 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb7250f2543c08eb6a4a0b51e32de4da http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_50559c669a4cca9d00980de2b65d34b6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e3330e3c88e8a904fa1b109dc7178a3f http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3950-3030 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b0731eea4be18b9d8eae72a589dc751b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6467498fe487b636ea4cc8f86796e24f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_868b47cacf9b98457dcabd4db7aa56c5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_968d68b9e6be33292b7e40907203541e
date	202001
identifier	https://doi.org/10.1080/2162402x.2020.1731072 https://pubmed.ncbi.nlm.nih.gov/32158623 https://pubmed.ncbi.nlm.nih.gov/PMC7051187
isPartOf	https://portal.issn.org/resource/ISSN/2162-402X http://rdf.ncbi.nlm.nih.gov/pubchem/journal/39616
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab
discusses	http://id.nlm.nih.gov/mesh/M000618590 http://id.nlm.nih.gov/mesh/M0556300
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D008175Q000188 http://id.nlm.nih.gov/mesh/D002289Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D011379 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D061067 http://id.nlm.nih.gov/mesh/D011446 http://id.nlm.nih.gov/mesh/D009154
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168

Showing number of triples: 1 to 51 of 51.